TRENDS: A Prospective Study of the Clinical Significance of Atrial Arrhythmias Detected by Implanted Device Diagnostics

NCT ID: NCT00279981

Last Updated: 2008-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-11-30

Study Completion Date

2007-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to look at the heart rate and rhythm information collected daily in Medtronic implantable pulse generators (IPG), implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT) devices. The study will gather this information from many patients to see if heart rate or rhythm data can predict the risk of a patient having a medical condition such as stroke.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Stroke Heart Failure

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Atrial fibrillation Stroke Pacemaker Implantable Cardiac Defibrillator Resynchronization systems

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diagnostic

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject provides written informed consent and privacy/protection authorization.
* Subjects 65 years of age or older.

OR

* Subjects with age \>18 and \< 65 years and one of the following stroke risk factors:
* Prior stroke or TIA
* Diagnosis of hypertension (HTN)
* Diagnosis of Diabetes Mellitus (DM)
* Diagnosis of Congestive Heart Failure (CHF)
* Subjects who meet the Class I/Class II indications for a dual chamber implantable pulse generator or dual chamber implanted cardioverter defibrillator device

OR

• Subjects who meet the criteria for indication of a dual chamber resynchronization device with bi-ventricular pacing (moderate to severe CHF symptoms \[NYHA Class III-IV\] despite optimal medical therapy, left ventricular ejection fraction ≤ 35%, and a QRS duration ≥130 ms)13.

Exclusion Criteria

* Subjects who are to receive a replacement IPG, ICD or CRT device.
* Subjects with chronic (permanent) AT/AF.
* Subjects with a history of AV nodal dependent arrhythmias.
* Subjects with a terminal illness who are not expected to survive more than 6 months.
* Subjects who are unwilling or unable to cooperate or give written informed consent and privacy/protection authorization, or subjects whose legal representatives or legal guardians refuse to give informed consent or privacy/protection authorization.
* Subjects currently receiving treatment in another drug and/or device study which could affect the outcome of the trial.
* Subjects who are or will be inaccessible for follow-up at a qualified study center.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic

INDUSTRY

Sponsor Role collaborator

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emile Daoud, MD

Role: PRINCIPAL_INVESTIGATOR

Riverside Hospital

Taya Glotzer, MD

Role: PRINCIPAL_INVESTIGATOR

Hackensack Meridian Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mesa, Arizona, United States

Site Status

Tucson, Arizona, United States

Site Status

Fountain Valley, California, United States

Site Status

Mission Viejo, California, United States

Site Status

Modesto, California, United States

Site Status

National City, California, United States

Site Status

Palm Springs, California, United States

Site Status

Salinas, California, United States

Site Status

San Bernadino, California, United States

Site Status

Torrance, California, United States

Site Status

Norwalk, Connecticut, United States

Site Status

Newark, Delaware, United States

Site Status

Washington D.C., District of Columbia, United States

Site Status

Fort Lauderdale, Florida, United States

Site Status

Hollywood, Florida, United States

Site Status

Melbourne, Florida, United States

Site Status

Naples, Florida, United States

Site Status

Palm Beach Gardens, Florida, United States

Site Status

St. Petersburg, Florida, United States

Site Status

Atlanta, Georgia, United States

Site Status

Boise, Idaho, United States

Site Status

Chicago, Illinois, United States

Site Status

Indianapolis, Indiana, United States

Site Status

Munster, Indiana, United States

Site Status

Ames, Iowa, United States

Site Status

Wichita, Kansas, United States

Site Status

Ashland, Kentucky, United States

Site Status

Lexington, Kentucky, United States

Site Status

Covington, Louisiana, United States

Site Status

Slidell, Louisiana, United States

Site Status

Baltimore, Maryland, United States

Site Status

Hagerstown, Maryland, United States

Site Status

Takoma Park, Maryland, United States

Site Status

Boston, Massachusetts, United States

Site Status

Brighton, Massachusetts, United States

Site Status

Burlington, Massachusetts, United States

Site Status

Worcester, Massachusetts, United States

Site Status

Grand Blanc, Michigan, United States

Site Status

Kalamazoo, Michigan, United States

Site Status

Mount Clemens, Michigan, United States

Site Status

Saginaw, Michigan, United States

Site Status

Duluth, Minnesota, United States

Site Status

Minneapolis, Minnesota, United States

Site Status

Saint Paul, Minnesota, United States

Site Status

Gulfport, Mississippi, United States

Site Status

Hattiesburg, Mississippi, United States

Site Status

Tupelo, Mississippi, United States

Site Status

St Louis, Missouri, United States

Site Status

Lincoln, Nebraska, United States

Site Status

Omaha, Nebraska, United States

Site Status

Lebanon, New Hampshire, United States

Site Status

Camden, New Jersey, United States

Site Status

Cherry Hill, New Jersey, United States

Site Status

Hackensack, New Jersey, United States

Site Status

Haddon Heights, New Jersey, United States

Site Status

West Orange, New Jersey, United States

Site Status

Brooklyn, New York, United States

Site Status

New York, New York, United States

Site Status

Poughkeepsie, New York, United States

Site Status

Syracuse, New York, United States

Site Status

Greensboro, North Carolina, United States

Site Status

Pinehurst, North Carolina, United States

Site Status

Raleigh, North Carolina, United States

Site Status

Winston-Salem, North Carolina, United States

Site Status

Cleveland, Ohio, United States

Site Status

Columbus, Ohio, United States

Site Status

Fairview Park, Ohio, United States

Site Status

Marion, Ohio, United States

Site Status

Toledo, Ohio, United States

Site Status

Midwest City, Oklahoma, United States

Site Status

Easton, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Charleston, South Carolina, United States

Site Status

Columbia, South Carolina, United States

Site Status

Greenville, South Carolina, United States

Site Status

Chattanooga, Tennessee, United States

Site Status

Knoxville, Tennessee, United States

Site Status

Memphis, Tennessee, United States

Site Status

Nashville, Tennessee, United States

Site Status

Austin, Texas, United States

Site Status

Corpus Christi, Texas, United States

Site Status

Dallas, Texas, United States

Site Status

Fort Worth, Texas, United States

Site Status

Houston, Texas, United States

Site Status

Odessa, Texas, United States

Site Status

Tyler, Texas, United States

Site Status

Charlottesville, Virginia, United States

Site Status

Norfolk, Virginia, United States

Site Status

Richmond, Virginia, United States

Site Status

Spokane, Washington, United States

Site Status

La Crosse, Wisconsin, United States

Site Status

Milwaukee, Wisconsin, United States

Site Status

Liverpool, New South Wales, Australia

Site Status

New Lambton, New South Wales, Australia

Site Status

Bedford Park, South Australia, Australia

Site Status

Perth-Western Australia, , Australia

Site Status

Calgary, Alberta, Canada

Site Status

London, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada

References

Explore related publications, articles, or registry entries linked to this study.

Yano Y, Greenland P, Lloyd-Jones DM, Daoud EG, Koehler JL, Ziegler PD. Simulation of Daily Snapshot Rhythm Monitoring to Identify Atrial Fibrillation in Continuously Monitored Patients with Stroke Risk Factors. PLoS One. 2016 Feb 16;11(2):e0148914. doi: 10.1371/journal.pone.0148914. eCollection 2016.

Reference Type DERIVED
PMID: 26882334 (View on PubMed)

Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009 Oct;2(5):474-80. doi: 10.1161/CIRCEP.109.849638. Epub 2009 Aug 4.

Reference Type DERIVED
PMID: 19843914 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

219

Identifier Type: -

Identifier Source: org_study_id